Medicago and GSK announce positive interim Phase 2 results for adjuvanted COVID-19 vaccine candidate

QUEBEC CITY and LONDON, May 18, 2021 /CNW/ - Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) are pleased to report positive interim Phase 2 clinical trial safety and immunogenicity data for Medicago's plant-derived COVID-19 vaccine candidate, which has been tested in combination with GSK's pandemic adjuvant. These results are part of the ongoing Phase 2/3 study and reiterate the promising profile observed during Phase 1 testing. Immunogenicity, as measured by the neutralizing antibody titer, was high - about 10 times higher than those in a panel of sera from patients recovering from COVID-19. No related severe adverse events were reported and reactogenicity was generally mild to moderate and short in duration.

NewsGuest UserMay 18, 2021Medicago, GSK, COVID-19 vaccine